Long-term study of a quadrivalent human papillomavirus vaccine

• Autor: Ferris, Daron ; Samakoses, Rudiwilai ; Block, Stan L ; Lazcano-Ponce, Eduardo ; Restrepo, Jaime Alberto ; Reisinger, Keith S ; Mehlsen, Jesper ; Chatterjee, Archana ; Iversen, Ole-Erik ; Sings, Heather L ; Shou, Qiong ; Sausser, Timothy A ; Saah, Alfred
• Assuntos: Adolescent ; Child ; Double-Blind Method ; Female ; Follow-Up Studies ; Human papillomavirus ; Human papillomavirus 11 - drug effects ; Human papillomavirus 11 - physiology ; Human papillomavirus 16 - drug effects ; Human papillomavirus 16 - physiology ; Human papillomavirus 18 - drug effects ; Human papillomavirus 18 - physiology ; Human papillomavirus 6 - drug effects ; Human papillomavirus 6 - physiology ; Humans ; Immunization ; Male ; Papillomavirus Infections - blood ; Papillomavirus Infections - epidemiology ; Papillomavirus Infections - prevention & control ; Papillomavirus Vaccines - administration & dosage ; Papillomavirus Vaccines - blood ; Pediatrics ; Time Factors ; Treatment Outcome ; Vaccination - trends ; Vaccines
• É parte de: Pediatrics (Evanston), 2014-09, Vol.134 (3), p.e657-e665
• Notas: ObjectType-Article-1
  SourceType-Scholarly Journals-1
  ObjectType-News-2
  ObjectType-Feature-3
  content type line 23
  ObjectType-Feature-2
  
• Descrição: We present a long-term safety, immunogenicity, and effectiveness study of a quadrivalent human papillomavirus (HPV4) vaccine. Sexually naive boys and girls aged 9 to 15 years (N = 1781) were assigned (2:1) to receive HPV4 vaccine or saline placebo at day 1 and months 2 and 6. At month 30, the placebo group (n = 482) received HPV4 vaccine following the same regimen and both cohorts were followed through month 96. Subjects ≥ 16 years were eligible for effectiveness evaluations. The primary objective was to evaluate the long-term anti-HPV6/11/16/18 serological levels. The secondary objective was to estimate vaccine effectiveness against HPV6/11/16/18-related persistent infection or disease. For each of the HPV4 vaccine types, vaccination-induced anti-HPV response persisted through month 96. Among 429 subjects who received HPV4 vaccine at a mean age of 12, none developed HPV6/11/16/18-related disease or persistent infection of ≥ 12 months' duration. Acquisition of new sexual partners (among those ≥ 16 years) was ∼1 per year. Subjects receiving HPV4 vaccine at month 30 (mean age 15 years) had a similar baseline rate of seropositivity to ≥ 1 of the 4 HPV types to those vaccinated at day 1 (mean age 12 years; 1.9% [9 of 474] vs 1.7% [20 of 1157]); however, 4 of the 9 subjects vaccinated at the later age were seropositive to 3 vaccine types, indicating previous HPV exposure. No new significant serious adverse events were observed for 8 years postvaccination in both genders. When administered to adolescents, the HPV4 vaccine demonstrated durability in clinically effective protection and sustained antibody titers over 8 years.
  
• Editor: United States: American Academy of Pediatrics
  
• Idioma: Inglês